Making the Call in Heart Failure
Multidimensional Outcomes With SGLT2 Inhibitors
Heart disease and stroke statistics-2020 update: a report from the American Heart Association.
Virani et al. Circulation. 2020;141(9):e139-e596.
How should we sequence the treatments for heart failure and a reduced ejection fraction?: a redefinition of evidence-based medicine.
McMurray et al. Circulation. 2021;143(9):875-877.
Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.
Zinman B, et al. N Engl J Med. 2015;373(22):2117-2128.
Canagliflozin and cardiovascular and renal events in type 2 diabetes.
Neal B, et al. N Engl J Med. 2017;377(7):644-657.
Dapagliflozin and cardiovascular outcomes in type 2 diabetes.
Wiviott SD, et al. N Engl J Med. 2019;380(4):347-357.
Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.
Perkovic V, et al. N Engl J Med. 2019;380(24):2295-2306.
Cardiovascular outcomes with ertugliflozin in type 2 diabetes.
Cannon CP, et al. N Engl J Med. 2020;383(15):1425-1435.
Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis.
McGuire D, et al. JAMA Cardiol. 2021;6(2):148–158.
SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
Zannad F, et al. Lancet. 2020;396:819-829.
Empagliflozin in heart failure with a preserved ejection fraction.
Anker et al. N Engl J Med. 2021;385(16):1451-1461.
Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction.
Solomon et al. N Engl J Med. 2022;387(12):1089-1098.
Clinical Practice Guidelines
2022 AHA/ACC/HFSA Guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
Heidenreich PA, et al. Circulation. 2022;145(18):e895-e1032.
2021 Update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction.
Maddox TM, et al. J Am Coll Cardiol. 2021;77(6):772-810.
2020 Expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes: a report of the American College of Cardiology Solution Set Oversight Committee.
Das, et al. J Am Coll Cardiol. 2020;76(9):1117-1145.
Clinician Resources
American College of Cardiology, Global CV Institute website, Heart Failure: Applying the Guidelines
Making the Call in Heart Failure
Multidimensional Outcomes with SGLT2 Inhibitors
| Faculty: | Biykem Bozkurt, MD, PhD, FHFSA, FACC, FAHA, FACP; Javed Butler, MD, MPH, MBA; Christopher P. Cannon, MD |
| Release: | 11/18/2022 |
| Expiration: | 11/18/2023 |
